Caplacizumab improves clinical outcomes and is well tolerated across clinically relevant subgroups of patients with immune-mediated thrombotic thrombocytopenic purpura.

ABSTRACT:

Background

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) may lead to microvascular thrombosis and mortality, despite patients receiving appropriate standard of care treatment (immunosuppressive therapy and therapeutic plasma exchange). Caplacizumab directly inhibits von Willebrand factor-platelet interaction and consequently prevents microthrombi formation.

Objectives

This study aimed to determine the efficacy and safety of caplacizumab in diverse, clinically relevant patient subgroups.

Methods

In this post hoc analysis of phase 3 HERCULES study (NCT02553317), patients were categorized by clinically relevant subgroups (prior iTTP history, iTTP severity at presentation, and initial immunosuppression regimen).

Results

In patients with previous acute

SUBMITTER: Pavenski K 

PROVIDER: S-EPMC11362790 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature